Brain Natriuretic Peptide Concentration in Dogs with Heart Disease and Congestive Heart Failure

Kristin A. MacDonald, Mark D Kittleson, Coralie Munro, Philip H Kass

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Plasma brain natriuretic peptide concentration ([BNP]) is high in humans with cardiac disease and is further increased with congestive heart failure (CHF). The hypotheses of this study were that dogs with moderate to severe mitral regurgitation due to myxomatous mitral valve disease (MVD) would have increased plasma [BNP] compared to normal dogs, that plasma [BNP] would be higher in dogs with CHF, and that plasma [BNP] would predict premature death from cardiovascular disease. The study population consisted of 34 dogs: 9 normal dogs and 25 dogs with MVD. Patients were divided into 4 groups: group I - 10 dogs with moderate to severe MVD and no radiographic evidence of CHF; group II - 6 dogs with severe MVD and mild CHF; group III - 7 dogs with severe MVD and moderate CHF; and group IV - 2 dogs with severe MVD and severe CHF. Diagnostic tests included thoracic radiographs, an echocardiogram, a serum chemistry profile, and the measurement of plasma [BNP] by a canine-specific radioimmunoassay. There was a significant positive correlation between the plasma [BNP] and heart disease/failure groups (P = .0036). Plasma [BNP] increased with progressively increasing severity of MVD and CHF. Group I dogs had higher plasma [BNP] than did control dogs (P < .0001), and plasma [BNP] was higher in dogs with CHF (groups II-IV versus group I; P = .012). Plasma [BNP] was also weakly positively correlated with left atrial size (r = 0.43, P = .04). For every 10-pg/mL increase in plasma [BNP], the mortality rate over 4 months' time increased approximately 44%.

Original languageEnglish (US)
Pages (from-to)172-177
Number of pages6
JournalJournal of Veterinary Internal Medicine
Volume17
Issue number2
DOIs
StatePublished - Mar 2003

Fingerprint

natriuretic peptides
Brain Natriuretic Peptide
heart diseases
heart failure
Heart Diseases
Heart Failure
Dogs
brain
dogs
Mitral Valve
Premature Mortality
blood chemistry
Mitral Valve Insufficiency
chest
Routine Diagnostic Tests
heart valve diseases
radioimmunoassays
Radioimmunoassay
Canidae
diagnostic techniques

Keywords

  • Diagnostic test
  • Mortality
  • Myxomatous mitral valve disease

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Brain Natriuretic Peptide Concentration in Dogs with Heart Disease and Congestive Heart Failure. / MacDonald, Kristin A.; Kittleson, Mark D; Munro, Coralie; Kass, Philip H.

In: Journal of Veterinary Internal Medicine, Vol. 17, No. 2, 03.2003, p. 172-177.

Research output: Contribution to journalArticle

@article{424feea94cea458db170fd5e8a185012,
title = "Brain Natriuretic Peptide Concentration in Dogs with Heart Disease and Congestive Heart Failure",
abstract = "Plasma brain natriuretic peptide concentration ([BNP]) is high in humans with cardiac disease and is further increased with congestive heart failure (CHF). The hypotheses of this study were that dogs with moderate to severe mitral regurgitation due to myxomatous mitral valve disease (MVD) would have increased plasma [BNP] compared to normal dogs, that plasma [BNP] would be higher in dogs with CHF, and that plasma [BNP] would predict premature death from cardiovascular disease. The study population consisted of 34 dogs: 9 normal dogs and 25 dogs with MVD. Patients were divided into 4 groups: group I - 10 dogs with moderate to severe MVD and no radiographic evidence of CHF; group II - 6 dogs with severe MVD and mild CHF; group III - 7 dogs with severe MVD and moderate CHF; and group IV - 2 dogs with severe MVD and severe CHF. Diagnostic tests included thoracic radiographs, an echocardiogram, a serum chemistry profile, and the measurement of plasma [BNP] by a canine-specific radioimmunoassay. There was a significant positive correlation between the plasma [BNP] and heart disease/failure groups (P = .0036). Plasma [BNP] increased with progressively increasing severity of MVD and CHF. Group I dogs had higher plasma [BNP] than did control dogs (P < .0001), and plasma [BNP] was higher in dogs with CHF (groups II-IV versus group I; P = .012). Plasma [BNP] was also weakly positively correlated with left atrial size (r = 0.43, P = .04). For every 10-pg/mL increase in plasma [BNP], the mortality rate over 4 months' time increased approximately 44{\%}.",
keywords = "Diagnostic test, Mortality, Myxomatous mitral valve disease",
author = "MacDonald, {Kristin A.} and Kittleson, {Mark D} and Coralie Munro and Kass, {Philip H}",
year = "2003",
month = "3",
doi = "10.1892/0891-6640(2003)017<0172:BNPCID>2.3.CO;2",
language = "English (US)",
volume = "17",
pages = "172--177",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Brain Natriuretic Peptide Concentration in Dogs with Heart Disease and Congestive Heart Failure

AU - MacDonald, Kristin A.

AU - Kittleson, Mark D

AU - Munro, Coralie

AU - Kass, Philip H

PY - 2003/3

Y1 - 2003/3

N2 - Plasma brain natriuretic peptide concentration ([BNP]) is high in humans with cardiac disease and is further increased with congestive heart failure (CHF). The hypotheses of this study were that dogs with moderate to severe mitral regurgitation due to myxomatous mitral valve disease (MVD) would have increased plasma [BNP] compared to normal dogs, that plasma [BNP] would be higher in dogs with CHF, and that plasma [BNP] would predict premature death from cardiovascular disease. The study population consisted of 34 dogs: 9 normal dogs and 25 dogs with MVD. Patients were divided into 4 groups: group I - 10 dogs with moderate to severe MVD and no radiographic evidence of CHF; group II - 6 dogs with severe MVD and mild CHF; group III - 7 dogs with severe MVD and moderate CHF; and group IV - 2 dogs with severe MVD and severe CHF. Diagnostic tests included thoracic radiographs, an echocardiogram, a serum chemistry profile, and the measurement of plasma [BNP] by a canine-specific radioimmunoassay. There was a significant positive correlation between the plasma [BNP] and heart disease/failure groups (P = .0036). Plasma [BNP] increased with progressively increasing severity of MVD and CHF. Group I dogs had higher plasma [BNP] than did control dogs (P < .0001), and plasma [BNP] was higher in dogs with CHF (groups II-IV versus group I; P = .012). Plasma [BNP] was also weakly positively correlated with left atrial size (r = 0.43, P = .04). For every 10-pg/mL increase in plasma [BNP], the mortality rate over 4 months' time increased approximately 44%.

AB - Plasma brain natriuretic peptide concentration ([BNP]) is high in humans with cardiac disease and is further increased with congestive heart failure (CHF). The hypotheses of this study were that dogs with moderate to severe mitral regurgitation due to myxomatous mitral valve disease (MVD) would have increased plasma [BNP] compared to normal dogs, that plasma [BNP] would be higher in dogs with CHF, and that plasma [BNP] would predict premature death from cardiovascular disease. The study population consisted of 34 dogs: 9 normal dogs and 25 dogs with MVD. Patients were divided into 4 groups: group I - 10 dogs with moderate to severe MVD and no radiographic evidence of CHF; group II - 6 dogs with severe MVD and mild CHF; group III - 7 dogs with severe MVD and moderate CHF; and group IV - 2 dogs with severe MVD and severe CHF. Diagnostic tests included thoracic radiographs, an echocardiogram, a serum chemistry profile, and the measurement of plasma [BNP] by a canine-specific radioimmunoassay. There was a significant positive correlation between the plasma [BNP] and heart disease/failure groups (P = .0036). Plasma [BNP] increased with progressively increasing severity of MVD and CHF. Group I dogs had higher plasma [BNP] than did control dogs (P < .0001), and plasma [BNP] was higher in dogs with CHF (groups II-IV versus group I; P = .012). Plasma [BNP] was also weakly positively correlated with left atrial size (r = 0.43, P = .04). For every 10-pg/mL increase in plasma [BNP], the mortality rate over 4 months' time increased approximately 44%.

KW - Diagnostic test

KW - Mortality

KW - Myxomatous mitral valve disease

UR - http://www.scopus.com/inward/record.url?scp=0038317942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038317942&partnerID=8YFLogxK

U2 - 10.1892/0891-6640(2003)017<0172:BNPCID>2.3.CO;2

DO - 10.1892/0891-6640(2003)017<0172:BNPCID>2.3.CO;2

M3 - Article

C2 - 12683617

AN - SCOPUS:0038317942

VL - 17

SP - 172

EP - 177

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 2

ER -